샘플 요청 목록

 카트 문의
시장보고서
상품코드
2067589

심혈관 임상시험 시장 규모, 점유율 및 동향 분석 보고서 : 단계별, 연구 디자인별, 적응증별, 연구 디자인, 적응증별, 스폰서별, 지역별 및 부문별 예측(2026-2033년)

Cardiovascular Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Indication by Study Design, By Indication, By Service, By Sponsor, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 9,056,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 10,578,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 13,622,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

심혈관 임상시험 시장 개요

세계의 심혈관 임상시험 시장 규모는 2025년에 122억 달러로 추정되며, 2033년에 216억 달러에 달할 것으로 예측되고 있으며, 2026-2033년에 CAGR 7.7%로 성장할 것으로 전망되고 있습니다.

이 시장의 성장을 주도하고 있는 요인은 전 세계 심혈관 질환(CVD)의 부담, 혁신적인 치료법에 대한 수요 증가, 제약 및 생명공학 기업의 연구개발(R&D) 투자 확대입니다.

시장 성장에 기여하고 있는 그 밖의 요인으로는 앉아 있는 시간이 많은 생활 습관, 고령화, 흡연 습관, 스트레스, 불건강한 식생활 등이 있으며, 이러한 요인들은 전 세계에서 심혈관 질환의 유병률을 현저히 높이고 있습니다. 또한 고혈압, 심부전, 뇌졸중, 관상동맥 질환의 환자 수가 증가하고 있는 점도 혁신적인 치료법과 의료기기에 대한 수요를 지원하고 있습니다. 따라서 환자의 예후를 개선하고, 합병증을 줄이며, 생존율을 높이기 위한 첨단 심혈관 치료법을 개발하기 위한 임상 연구 활동이 확대되고 있습니다.

심혈관 임상시험 산업은 전 세계에서 증가하는 심혈관 질환(CVD)의 부담과 혁신적인 치료법에 대한 수요 증가에 힘입어 성장하고 있습니다. 심혈관 질환은 여전히 전 세계에서 주요 사망 원인이며, 이에 따라 효과적인 의약품, 의료기기 및 예방적 치료법에 대한 필요성이 커지고 있습니다. 예를 들어 미국심장협회(AHA) 회장 자문위원회는 심혈관 질환과 관련된 위험 요인의 부담이 향후 수십 년 동안 크게 증가할 것으로 예측된다고 밝혔습니다. 2050년까지 미국의 심혈관 질환 유병률은 인구의 약 11.3%에서 15% 가까이 증가할 것으로 예상되며, 약 4,500만 명의 성인이 영향을 받을 가능성이 있습니다.

또한 뇌졸중 환자 수도 크게 증가하여, 성인 환자 수가 약 1,000만 명에서 2,000만 명 가까이까지 늘어날 것으로 예상됩니다. 또한 심혈관 질환의 주요 원인 중 하나인 비만의 유병률은 인구의 약 43%에서 60% 이상으로 확대될 것으로 예상됩니다. 이러한 예측은 보다 강력한 예방 의료 전략, 위험 요인 관리의 개선, 심혈관 및 대사 질환의 예방 및 치료에 대한 투자 확대가 시급히 필요함을 여실히 보여주고 있습니다. 이러한 상황에 따라 많은 제약사와 생명공학 기업은 심부전, 고혈압, 부정맥, 허혈성 심장질환, 이상지질혈증 등 다양한 심혈관 질환에 대한 첨단 치료법을 개발하기 위해 연구 투자를 확대하고 있습니다. 이러한 치료 파이프라인의 확대가 전문적인 임상시험 서비스에 대한 수요를 지원하고 있습니다.

자주 묻는 질문

  • 심혈관 임상시험 시장 규모는 어떻게 예측되나요?
  • 심혈관 임상시험 시장의 성장을 주도하는 요인은 무엇인가요?
  • 심혈관 질환의 유병률 증가에 영향을 미치는 요인은 무엇인가요?
  • 미국의 심혈관 질환 유병률은 어떻게 변화할 것으로 예상되나요?
  • 뇌졸중 환자 수는 어떻게 변화할 것으로 예상되나요?
  • 비만의 유병률은 어떻게 변화할 것으로 예상되나요?
  • 심혈관 질환에 대한 연구 투자 확대의 배경은 무엇인가요?

목차

제1장 연구 방법과 범위

제2장 개요

제3장 심혈관 임상시험 시장 : 변수, 동향, 범위

제4장 심혈관 임상시험 시장 : 단계별, 추정·동향 분석

제5장 심혈관 임상시험 시장 : 연구 디자인별, 추정·동향 분석

제6장 심혈관 임상시험 시장 : 적응증별, 추정·동향 분석

제7장 심혈관 임상시험 시장 : 연구 디자인·적응증별, 추정·동향 분석

제8장 심혈관 임상시험 시장 : 서비스별, 추정·동향 분석

제9장 심혈관 임상시험 시장 : 스폰서별, 추정·동향 분석

제10장 심혈관 임상시험 시장 : 지역별, 추정·동향 분석

제11장 경쟁 구도

KSA 26.06.30

Cardiovascular Clinical Trials Market Summary

The global cardiovascular clinical trials market size was estimated at USD 12.2 billion in 2025 and is projected to reach USD 21.6 billion by 2033, growing at a CAGR of 7.7% from 2026 to 2033. The market is driven by the global burden of cardiovascular diseases (CVDs), growing demand for innovative therapies, and rising R&D investments by pharmaceutical and biotech companies.

Some other factors contributing to market growth are sedentary lifestyles, aging populations, smoking habits, stress, and unhealthy diets, which are significantly increasing the prevalence of cardiovascular diseases worldwide. Besides, rising cases of hypertension, heart failure, stroke, and coronary artery disease are driving demand for innovative therapies and medical devices. Thus, clinical research activities are expanding to develop advanced cardiovascular treatments that improve patient outcomes, reduce complications, and enhance survival rates.

The cardiovascular clinical trials industry is driven by the increasing global burden of cardiovascular diseases (CVDs) and a growing demand for innovative therapies. CVDs continue to be a leading cause of mortality worldwide, driving the need for effective drugs, medical devices, and preventive treatments. For instance, the American Heart Association Presidential Advisory mentioned that the burden of cardiovascular disease and associated risk factors is projected to rise substantially over the coming decades. By 2050, cardiovascular disease prevalence in the U.S. is anticipated to grow from approximately 11.3% to nearly 15% of the population, potentially impacting around 45 million adults.

In addition, stroke cases are expected to increase significantly, rising from nearly 10 million to close to 20 million adults. In addition, obesity, one of the primary contributors to cardiovascular disorders, is expected to expand from about 43% of the population to over 60%. These projections highlight the urgent need for stronger preventive healthcare strategies, improved risk-factor management, and greater investment in cardiometabolic disease prevention and treatment initiatives. This has led most pharmaceutical and biotechnology companies to boost their investments in research to develop advanced treatments for various cardiovascular conditions, including heart failure, hypertension, arrhythmias, ischemic heart disease, and lipid disorders. This expanding pipeline of therapeutics fuels the demand for specialized clinical trial services.

Global Cardiovascular Clinical Trials Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cardiovascular clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and region:

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Valvular Heart Disease
  • Peripheral Artery Disease
  • Ischemic Heart Disease
  • Pulmonary Arterial Hypertension
  • Stroke
  • Cardiac Arrhythmias
  • Heart Failure
  • Other Indications
  • Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Valvular Heart Disease
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Peripheral Artery Disease
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Ischemic Heart Disease
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Pulmonary Arterial Hypertension
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Stroke
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Cardiac Arrhythmias
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Heart Failure
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Other Indications
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Protocol Designing
  • Site Identification
  • Patient Recruitment
  • Laboratory Services
  • Analytical Testing Services
  • Clinical Trial Data Management Services
  • Others
  • Sponsor Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
    • Columbia
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
    • Qatar
    • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Phase
    • 1.2.2. Study Design
    • 1.2.3. Indication
    • 1.2.4. Indication by Study Design
    • 1.2.5. Service
    • 1.2.6. Sponsor
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Botton-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cardiovascular Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising burden of cardiovascular diseases globally
      • 3.2.1.2. Globalization of clinical trials
      • 3.2.1.3. Increasing R&D investment in cardiovascular clinical trials
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rigorous approval standards set by regulatory bodies
      • 3.2.2.2. Patient recruitment and retention challenges
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Force Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Cardiovascular Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Cardiovascular Clinical Trials Market, By Phase: Segment Dashboard
  • 4.2. Cardiovascular Clinical Trials Market, By Phase: Movement Analysis
  • 4.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Phase, 2021 - 2033 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cardiovascular Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Cardiovascular Clinical Trials Market, By Study Design: Segment Dashboard
  • 5.2. Cardiovascular Clinical Trials Market, By Study Design: Movement Analysis
  • 5.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Study Design, 2021 - 2033 (USD Million)
  • 5.4. Interventional Trials
    • 5.4.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Observational Trials
    • 5.5.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Expanded Access Trials
    • 5.6.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cardiovascular Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Cardiovascular Clinical Trials Market, By Indication: Segment Dashboard
  • 6.2. Cardiovascular Clinical Trials Market, By Indication: Movement Analysis
  • 6.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
  • 6.4. Valvular Heart Disease
    • 6.4.1. Valvular Heart Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Peripheral Artery Disease
    • 6.5.1. Peripheral Artery Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Ischemic Heart Disease
    • 6.6.1. Ischemic Heart Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Pulmonary Arterial Hypertension
    • 6.7.1. Pulmonary Arterial Hypertension Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Stroke
    • 6.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Cardiac Arrhythmias
    • 6.9.1. Cardiac Arrhythmias Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Heart Failure
    • 6.10.1. Heart Failure Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Other Indications
    • 6.11.1. Other Indications Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cardiovascular Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. Cardiovascular Clinical Trials Market, By Indication by Study Design: Segment Dashboard
  • 7.2. Cardiovascular Clinical Trials Market, By Indication by Study Design: Movement Analysis
  • 7.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Indication by Study Design, 2021 - 2033 (USD Million)
  • 7.4. Valvular Heart Disease
    • 7.4.1. Valvular Heart Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Interventional Trials
      • 7.4.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Observational Trials
      • 7.4.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Expanded Access Trials
      • 7.4.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Peripheral Artery Disease
    • 7.5.1. Peripheral Artery Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Interventional Trials
      • 7.5.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Observational Trials
      • 7.5.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Expanded Access Trials
      • 7.5.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Ischemic Heart Disease
    • 7.6.1. Ischemic Heart Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Interventional Trials
      • 7.6.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Observational Trials
      • 7.6.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. Expanded Access Trials
      • 7.6.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Pulmonary Arterial Hypertension
    • 7.7.1. Pulmonary Arterial Hypertension Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Interventional Trials
      • 7.7.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Observational Trials
      • 7.7.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. Expanded Access Trials
      • 7.7.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Stroke
    • 7.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Interventional Trials
      • 7.8.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Observational Trials
      • 7.8.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. Expanded Access Trials
      • 7.8.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Cardiac Arrhythmias
    • 7.9.1. Cardiac Arrhythmias Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.2. Interventional Trials
      • 7.9.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.3. Observational Trials
      • 7.9.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.4. Expanded Access Trials
      • 7.9.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Heart Failure
    • 7.10.1. Heart Failure Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.2. Interventional Trials
      • 7.10.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.3. Observational Trials
      • 7.10.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.4. Expanded Access Trials
      • 7.10.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Other Indications
    • 7.11.1. Other Indications Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.2. Interventional Trials
      • 7.11.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.3. Observational Trials
      • 7.11.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.4. Expanded Access Trials
      • 7.11.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Cardiovascular Clinical Trials Market: Service Estimates & Trend Analysis

  • 8.1. Cardiovascular Clinical Trials Market, By Service: Segment Dashboard
  • 8.2. Cardiovascular Clinical Trials Market, By Service: Movement Analysis
  • 8.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 8.4. Protocol Designing
    • 8.4.1. Protocol Designing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Site Identification
    • 8.5.1. Site Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Patient Recruitment
    • 8.6.1. Patient Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Laboratory Services
    • 8.7.1. Laboratory Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Analytical Testing Services
    • 8.8.1. Analytical Testing Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Clinical Trial Data Management Services
    • 8.9.1. Clinical Trial Data Management Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Others
    • 8.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Cardiovascular Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 9.1. Cardiovascular Clinical Trials Market, By Sponsor: Segment Dashboard
  • 9.2. Cardiovascular Clinical Trials Market, By Sponsor: Movement Analysis
  • 9.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Sponsor, 2021 - 2033 (USD Million)
  • 9.4. Pharmaceutical & Biopharmaceutical Companies
    • 9.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medical Device Companies
    • 9.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Others
    • 9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Cardiovascular Clinical Trials Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Dashboard
  • 10.2. Regional Market Share Analysis, 2025 & 2033
  • 10.3. North America
    • 10.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.3.2. U.S
      • 10.3.2.1. Key Country Dynamics
      • 10.3.2.2. Competitive Scenario
      • 10.3.2.3. Regulatory Framework
      • 10.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.3.3. Canada
      • 10.3.3.1. Key Country Dynamics
      • 10.3.3.2. Competitive Scenario
      • 10.3.3.3. Regulatory Framework
      • 10.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.3.4. Mexico
      • 10.3.4.1. Key Country Dynamics
      • 10.3.4.2. Competitive Scenario
      • 10.3.4.3. Regulatory Framework
      • 10.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4. Europe
    • 10.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.2. UK
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.3. Germany
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.4. France
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.5. Italy
      • 10.4.5.1. Key Country Dynamics
      • 10.4.5.2. Competitive Scenario
      • 10.4.5.3. Regulatory Framework
      • 10.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.6. Spain
      • 10.4.6.1. Key Country Dynamics
      • 10.4.6.2. Competitive Scenario
      • 10.4.6.3. Regulatory Framework
      • 10.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.7. Denmark
      • 10.4.7.1. Key Country Dynamics
      • 10.4.7.2. Competitive Scenario
      • 10.4.7.3. Regulatory Framework
      • 10.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.8. Sweden
      • 10.4.8.1. Key Country Dynamics
      • 10.4.8.2. Competitive Scenario
      • 10.4.8.3. Regulatory Framework
      • 10.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.9. Norway
      • 10.4.9.1. Key Country Dynamics
      • 10.4.9.2. Competitive Scenario
      • 10.4.9.3. Regulatory Framework
      • 10.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5. Asia Pacific
    • 10.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.2. Japan
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Framework
      • 10.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.3. China
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Framework
      • 10.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.4. India
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Framework
      • 10.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.5. Australia
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Framework
      • 10.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.6. Thailand
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Framework
      • 10.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.5.7. South Korea
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Framework
      • 10.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6. Latin America
    • 10.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.6.2. Brazil
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Framework
      • 10.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.6.3. Argentina
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Framework
      • 10.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.6.4. Columbia
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Framework
      • 10.6.4.4. Columbia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7. MEA
    • 10.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.7.2. South Africa
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Framework
      • 10.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.7.3. UAE
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Framework
      • 10.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.7.4. Saudi Arabia
      • 10.7.4.1. Key Country Dynamics
      • 10.7.4.2. Competitive Scenario
      • 10.7.4.3. Regulatory Framework
      • 10.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.7.5. Kuwait
      • 10.7.5.1. Key Country Dynamics
      • 10.7.5.2. Competitive Scenario
      • 10.7.5.3. Regulatory Framework
      • 10.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.7.6. Qatar
      • 10.7.6.1. Key Country Dynamics
      • 10.7.6.2. Competitive Scenario
      • 10.7.6.3. Regulatory Framework
      • 10.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.7.7. Oman
      • 10.7.7.1. Key Country Dynamics
      • 10.7.7.2. Competitive Scenario
      • 10.7.7.3. Regulatory Framework
      • 10.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Key Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
  • 11.3. Company Profiles
    • 11.3.1. IQVIA Inc.
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. ICON plc
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. SGS SA
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Eli Lilly and Company
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. PPD Inc.
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Syneos Health
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Caidya
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. Worldwide Clinical Trials
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Veeda Clinical Research
      • 11.3.9.1. Company Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. Parexel International (MA) Corporation
      • 11.3.10.1. Company Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. Medpace Holdings, Inc.
      • 11.3.11.1. Company Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Charles River Laboratories
      • 11.3.12.1. Company Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. MAC Research
      • 11.3.13.1. Company Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. Sofpromed
      • 11.3.14.1. Company Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. Laboratory Drug Development
      • 11.3.15.1. Company Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives
    • 11.3.16. AstraZeneca
      • 11.3.16.1. Company Overview
      • 11.3.16.2. Financial Performance
      • 11.3.16.3. Service Benchmarking
      • 11.3.16.4. Strategic Initiatives
    • 11.3.17. Novartis
      • 11.3.17.1. Company Overview
      • 11.3.17.2. Financial Performance
      • 11.3.17.3. Service Benchmarking
      • 11.3.17.4. Strategic Initiatives
    • 11.3.18. Pfizer
      • 11.3.18.1. Company Overview
      • 11.3.18.2. Financial Performance
      • 11.3.18.3. Service Benchmarking
      • 11.3.18.4. Strategic Initiatives
    • 11.3.19. Bristol Myers Squibb
      • 11.3.19.1. Company Overview
      • 11.3.19.2. Financial Performance
      • 11.3.19.3. Service Benchmarking
      • 11.3.19.4. Strategic Initiatives
    • 11.3.20. Johnson & Johnson
      • 11.3.20.1. Company Overview
      • 11.3.20.2. Financial Performance
      • 11.3.20.3. Service Benchmarking
      • 11.3.20.4. Strategic Initiatives
×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
문의하기